The News.
The Florey and Novapep are awarded a FightMND grant.
DECEMBER, 2025
Prof Brad Turner at The Florey Institute of Neuroscience and Mental Health was awarded a $550k FightMND drug development grant to develop Novapep's NVP-400 Series in Amyotrophic Lateral Sclerosis (ALS) over 2026 and 2027.
Swinburne Ventures Limited, the ventures vehicle of Swinburne University of Technology, has invested in Novapep to facilitate the modification of the native peptide G10 to significantly increase its half-life - the NVP-300 series for the treatment of severe Community-acquired pneumonia, and to make it available across the blood-brain-barrier for the treatment of neurodegenerative diseases - NVP-400 series.
NVP-202 DSS colitis study data presented as a poster at the European Gastroenterology Conference.
OCTOBER, 2024
Swinburne Ventures Limited invests in Novapep.
SEPTEMBER, 2025
At the European Gastroenterology Conference in Vienna in October 2024, Phoenixlab and Novapep presented a poster with key data from G10 in the DSS colitis model. The two key figures in the poster were:
G10 DSS colitis study data presented as a poster at the European Gastroenterology Conference.
OCTOBER, 2024
Novapep Pty Ltd is pleased to announce it recently closed a $1.5 million funding round. The investment was led by a syndicate of Sydney Angels members with previous investors including the University of Sydney.
Novapep secures $1.5 million equity funding to develop novel anti-inflammatory and cytoprotective peptide.
AUGUST, 2024
Prof John Griffin's NVP-202/ G10 paper published in the Journal of Thrombosis and Hemostatis.
JULY, 2024
An orthosteric/allosteric bivalent peptide agonist comprising covalently linked protease-activated receptor-derived peptides mimics in vitro and in vivo activities of activated protein C
NVP-202 ('G10') reduced murine death from i.p. endotoxin/LPS. Survival improved from 31% to 53% with only one i.v. dose of 2 mg/kg at 4 hours after LPS.